

## Special Issue

# Cutting-Edge Cancer Vaccines Enhanced by Nanotechnology

### Message from the Guest Editor

Cancer immunotherapies have significantly extended the survival time of cancer patients, revolutionized cancer treatment and opened a new era of cancer treatment. In particular, nanotechnology can protect the delivery of antigens, enable sustained and efficient antigen delivery to specific targets, enhance immunogenicity, and induce specific immune responses. Therefore, nanotechnology has played an indispensable role in the success of various clinical and preclinical vaccines. In this Special Issue, original research articles and reviews related to the recent advances, current challenges and future perspectives in cutting-edge nanotechnology-based cancer vaccines are welcome. Research areas may include the following:

- Nanoscale synthesis, structural regulation and functional design of polymers, lipids, inorganic particles and bio-derived materials for cancer vaccines;
- Nano-vaccine adjuvants for therapeutic, prophylactic and in situ cancer vaccines;
- Nanotechnology-based cancer vaccines combined with other cancer therapies, such as immune checkpoint inhibitors;
- Mechanisms, safety and efficacy of nanotechnology-enhanced cancer vaccines.

### Guest Editor

Dr. Xiupeng Wang

Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1, Higashi, Tsukuba, Ibaraki 305-8566, Japan

### Deadline for manuscript submissions

31 December 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/198951](https://mdpi.com/si/198951)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).